605680-62-4

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-2-[(5-trifluoromethylpyridin-2-yl)oxy]propionic acid is used as a pharmaceutical agent for its electron-conductive properties and potential to enhance the activity of other pharmaceutical agents. Its unique structure, which includes a pyridin group and a trifluoromethyl group, may contribute to the development of new drugs with improved efficacy and stability.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 2-Methyl-2-[(5-trifluoromethylpyridin-2-yl)oxy]propionic acid is used as a research compound to explore its potential applications in drug development. Its electron-conductive properties and the ability to increase the activity of pharmaceutical agents make it a valuable candidate for further investigation into its therapeutic potential.
Used in Drug Delivery Systems:
2-Methyl-2-[(5-trifluoromethylpyridin-2-yl)oxy]propionic acid may be employed in the development of drug delivery systems, where its lipophilicity and stability could be utilized to improve the bioavailability and therapeutic outcomes of pharmaceutical agents. Its unique structure could potentially allow for targeted drug delivery and enhanced drug efficacy.

InChI:InChI=1/C10H10F3NO3/c1-9(2,8(15)16)17-7-4-3-6(5-14-7)10(11,12)13/h3-5H,1-2H3,(H,15,16)

Upstream product

• 33252-63-0 2-hydroxy-5-(trifluoromethyl)pyridine 
• 52334-81-3 2-chloro-5-trifluoromethylpyridine 
• 80-55-7 ethyl 2-hydroxy-2,2-dimethylethanoate 
• 913849-17-9 ethyl 2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoate 

Downstream Products

• 701977-09-5 taranabant 
• 701977-00-6 N-[(1R,2R)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 721430-07-5 N-{[3-(4-chlorophenyl)-2-(3-bromophenyl)-2-hydroxy]propyl}-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide 
• 947371-19-9 C₂₇H₂₄ClF₄N₃O₂ 
• 1097207-71-0 C₂₈H₂₈Cl₂F₃N₃O₄ 
• 876365-72-9 3-{(1S,2S)-1-(4-chlorobenzyl)-2-[(2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanoyl)amino]propyl}benzamide 
• 876365-70-7 N-[(1Z)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylprop-1-en-1-yl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide 
• 1356556-88-1 4-(4-fluoro-3-(4-(2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanoyl)piperazine1l-carbonyl)benzyl)phthalazin-1(2H)-one 
• 1244978-38-8 C₂₈H₂₈ClF₃N₂O₂ 
• 1244978-34-4 C₂₇H₂₆ClF₃N₂O₂ 
• 1244978-30-0 C₂₆H₂₄ClF₃N₂O₂ 
• 1244978-13-9 C₂₇H₂₇BrClF₃N₂O₂ 
• 1092698-93-5 N-[(2S,3R)-4-(4-chlorophenyl)-3-(3-cyanophenyl)-1-(1H-1,2,4-triazol-1-yl)butan-2-yl]-2-methyl-2-[5-(trifluoromethyl)pyridin-2-yloxy]propanamide 
• 605679-35-4 N-[2-(3-cyano-5-fluoro-phenyl)-3-(4-chlorophenyl)-1-methylpropyl]-2-(5-trifluoromethyl-2-pyridyloxy)-2-methylpropanamide 

Relevant academic research and scientific papers

SUBSTITUTED 4-(4-FLUORO-3-(PIPERAZINE-1- CARBONYL)BENZYL)PHTHALAZIN-1(2H)-ONE DERIVATIVES AS POLY (ADP-RIBOSE) POLYMERASE- 1 INHIBITORS

Disclosed are compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts. These compounds are suitable as Poly (ADP-ribose) polymerase- 1 inhibitors (PARP-1 inhibitors).

PRO-DRUGS OF TERTIARY ALCOHOLS

The compounds of the present invention are prodrugs of modulators of the Cannabinoid-1 (CB 1 ) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the Cannabinoid- 1 (CB 1) receptor. In particular, compounds of the

ACYCLIC HYDRAZIDES AS CANNABINOID RECEPTOR MODULATORS

The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present inventio

Discovery of N-[(1S,2S)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1- methylpropyl]-2-methyl-2-{[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity

The discovery of novel acyclic amide cannabinoid-1 receptor inverse agonists is described. They are potent, selective, orally bioavailable, and active in rodent models of food intake and body weight reduction. A major focus of the optimization process was to increase in vivo efficacy and to reduce the potential for formation of reactive metabolites. These efforts led to the identification of compound 48 for development as a clinical candidate for the treatment of obesity.

COMBINATION OF DIPEPTIDYL PEPTIDASE-IV INHIBITOR AND A CANNABINOID CB1 RECEPTOR ANTAGONIST FOR THE TREATMENT OF DIABETES AND OBESITY

The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-IV (DPP-IV) inhibitor and a particular cannabinoid CB?1#191 receptor antagonist/inverse agonist, kits containing such combinations and methods of using such compositions for the treatment of diabetes, diabetes associated with obesity, diabetes-related disorders, obesity, and obesity-related disorders.

RADIOLABELED CANNABINOID-1 RECEPTOR MODULATORS

The present invention relates to particular radiolabeled Cannabinoid-1 (CB1) receptor modulators, and methods of using these modulators for labeling and diagnostic imaging of Cannabinoid-1 receptors in mammals, particularly humans. In addition, intermediates useful for the synthesis of the radiolabeled Cannabinoid-1 receptor modulators are also disclosed, as well as the processes for synthesizing the radiolabeled Cannabinoid-1 receptor modulators. Still further, formulations of the radiolabeled Cannabinoid-1 receptor compounds are described.

SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR

Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson s disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.